Join the Iowa Biotechnology Association
The Iowa Biotechnology Association (IBA) was formed in 1994 to advance opportunities in Iowa for the improvement of the
human environmental and economic well-being through the development and application of value-added technologies in the
life sciences.
Working cooperatively, the members hope to enhance the ability to commercialize new technologies in a
timely manner and reduce the lead time for deployment. Activities of the association are designed to give companies
doing business in Iowa an edge in delivering timely new products to consumers through the sharing of ideas regarding
the transfer and development of technologies.
More...
|
|
Learn About Iowa's BioHistory
Why is there a biotechnology industry in Iowa? Will the industry continue
to grow in Iowa? What do other states have? Each state has a unique story
that explains why a given industry has developed in a specific region and not in others.
Through Iowa BioHistory, you can learn about the scientists,
institutions, political leaders, and significant events that have shaped and are still shaping
the biotechnology, medical device and life science industries in the state of Iowa.
More IA BioHistory...
|
|
|
Local News...
Free News Release Posting & Archiving Service
- Stereotaxis' market leadership highlighted at Heart Rhythm 2008 Stereotaxis announced that its participation at Heart Rhythm 2008 reflects the broad market leadership it has achieved as the only provider of fully automated, remote navigation technology for cardiac ablation.
Stereotaxis, Inc. May 09, 2008
- Spectrum announces sale of injectable generic drugs to Sagent Spectrum Pharmaceuticals announced that it has sold its abbreviated new drug applications for its injectable generic drugs, ondansetron, carboplatin, fludarabine, and mitoxantrone, to Sagent Pharmaceuticals.
Spectrum Pharmaceuticals, Inc. May 09, 2008
- Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye Bayer HealthCare and development partner Regeneron Pharmaceuticals announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.
Bayer May 08, 2008
- AstraZeneca submits sNDA for Seroquel XR for the treatment of generalised anxiety disorder AstraZeneca announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for SEROQUEL XR(TM) Extended-Release Tablets to seek approval for the treatment of generalised anxiety disorder, including maintenance of antianxiety effect.
AstraZeneca May 08, 2008
- Invitrogen and WARF sign license agreement for human embryonic stem cells Invitrogen and the Wisconsin Alumni Research Foundation, the private, non-profit patenting and licensing organization for the University of Wisconsin-Madison, announced that they have signed a license for human embryonic stem cell patents for the development of research tools.
Invitrogen Corporation May 08, 2008
More... | Submit News Release | National News
|
New Job Postings...
Free Job Posting Trial Offer
More... |
Job Advertising...
| About Job Postings...
|
Upcoming Events...
Free Event Posting Service
More... |
Submit Event |
Event Advertising...
|
Deutsch |
Español |
Français |
Norsk |
Russian
|